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Abstract
Development of Radiochemical Quality Control Methods for 223Ra and 227Th Radiotherapies
By
Abigail Meghan Hasson
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2021
Research Advisor: Professor Daniel Thorek

Introduction. Radiolabeled molecules for use in disease detection and targeted treatment
are a mainstay of patient management. The majority of radiopharmaceuticals deployed to date
undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters,
which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals,
and there is a need for the proper validation of content and purity using common quality control
instrumentation. Hypothesis. There is a need for proper characterization of complex emitters for
more accurate quality control on readily available equipment. Here, we demonstrate the novel
characterization of 227Th and 223Ra using a solid-state semiconductor alpha detector, a gamma
counter, and a radio-TLC scanner, three widely accessible technologies. Results. In this work,
we validate the ability of the alpha particle spectral imaging camera and the gamma counter to
distinguish 227Th from 223Ra, allowing for fast, qualitative, and quantitative determination of
radionucleic purity. We also assess the utility and accuracy of the Bioscan radio-TLC to measure
these radionuclides under different high voltage settings. Finally, we validate our results and
demonstrate the practical applications of this work through evaluation of a 227Th-labeled
antibody construct. Conclusion. Our results develop a novel quality control protocol for 227Th

v
and 223Ra on three different, readily available instruments. These results can be applied to both
research and clinical settings as new alpha particle therapies are developed for cancer treatment.

1

Chapter 1: Introduction and Motivations

The introduction of radiation into the medical field permanently changed the possibilities
of healthcare and treatment. From its many imaging capabilities to treating cancerous tumors,
radionuclides continue to have a profound effect on modern medicine. In this chapter, we review
the history of nuclear medicine, the basics of radioactive decay, the current state-of-the-art
therapeutics in the field, and the regulations maintained for these radiopharmaceuticals. Finally,
we describe the motivations behind this thesis and the broader implications for the field.

1.1

A Brief History of Nuclear Medicine

At the end of the 19th century, Wilhelm Conrad Roentgen became the first pioneer in the field
of radioactivity when he discovered the x-ray during experimentation with a cathode ray tube. His
investigations led to the breakthrough that x-rays pass through soft tissue, but not bone, and he is
credited with capturing the first x-ray images [1]. It was not long before the medical community
realized the implications of his findings. The following year, Henri Becquerel discovered natural
radioactivity, and he shared the Nobel Prize in Physics with Marie and Pierre Curie [1]. However,
the most important milestone in nuclear medicine development is often considered the discovery
of artificial radioactivity by Irène and Frédéric Joliot-Curie and the invention of the cyclotron by
Ernest Lawrence, both in the 1930s [2][3]. Taken together, these advancements provided a
sufficient source of radioactivity for medical and biological research purposes. Soon after, the
medical community began examining the potential of radioactivity to treat ailments such as lupus
and cancer [1].
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During the early days, there was very little concern over any unintended consequences
associated with radioactive materials. This was partially due to the slow onset of symptoms,
although Pierre Curie did note that exposure to Radium for multiple days left a sore that was
‘difficult to heal’ [1]. Today, there is a long history of the connection between radiation exposure
and cancer incidence, which is attributed not to animal studies but to human experience [4].
The widespread use of nuclear medicine to treat, diagnose, and assess various diseases began
in the early 1950s [3]. Diagnostic nuclear medicine began with in vitro studies but soon progressed
to in vivo methods with the invention of the rectilinear scanner in 1949, which allowed for the
distribution of a radiopharmaceutical in an organ to be measured [5][6]. Early diagnostic
applications also included testing for blood perfusion, kidney function, and early signs of tumor
development [5]. By the late 20th century, diagnostic testing improved dramatically with the
advent of positron emission tomography (PET) and computerized tomography (CT), considered
two of the principal advancements in nuclear medicine in the last 50 years. Together, these
technologies allow for the detection of cancer, with low noise, rapid acquisition, and good spatial
resolution [7].
Additionally, nuclear medicine involves the treatment of various diseases. Early studies
focused on using radioisotopes to study and treat disorders of the thymus. In the early 1940s,
medical practitioners began using 32P for treatment of leukemia and bone metastases and

131I

for

the treatment of hyperthyroidism [5]. Eventually, the choice of radionuclide evolved as did the
types of cancers that could be treated. In the last 20 years, radioimmunotherapy has been of
increasing interest to researchers [8]. This method uses an antibody to deliver a radioactive isotope
directly to a tumor. It is highly customizable for each patient and avoids many adverse side effects
incurred on healthy organs during traditional radiotherapy [4]. There have been remarkable
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advancements in the field of nuclear medicine in the last century, and today these therapies are
still regarded as safe, non-invasive, and effective for the treatment of many diseases.
Advancements are made every year in the field and have the potential to greatly improve treatment
options and diagnostic methods.

1.2

Radioactive Decay

Energy that is absorbed in a biological source from radiation can cause ionization, which
occurs when there is sufficient energy to eject one or more electrons from an atom. This ionizing
radiation can be broken into two categories: electromagnetic and particulate [4]. Two examples of
electromagnetic radiation are gamma rays and x-rays, which can be considered as both waves of
energy and streams of photons [4]. Particulate radiation, on the other hand, includes electrons,
protons, neutrons, alpha particles, negative 𝜋-mesons, and heavy charged ions. These particles
have a mass component and may be charged [9].
Ionizing radiation is produced by radioactive decay, which occurs when a parent isotope
decays into its daughter radionuclide by releasing either gamma, beta, or alpha ionizing radiation
[10]. This decay is an exponential, statistically random first-order process, and the time at which
an individual radioatom will undergo decay cannot be predicted. However, the time at which a
large number of radioatoms will decay can be predicted very accurately by the half-life of the
radioactive species [10][11][12].
The forms of ionizing radiation released during radioactive decay differ in their composition,
formation, and energy. Alpha particles consist of 2 protons and 2 neutrons and are commonly
emitted during the decay of heavy, naturally occurring or man-made radionuclides. These particles
are large and positively charged, so they do not penetrate more than a few inches of air or a layer
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of cells. They carry an energy typically between 4-8 MeV [13]. Beta rays, another form of ionizing
radiation that may be emitted during radioactive decay, are high speed electrons or positrons [13].
They are smaller than alpha particles and are able to travel farther through air. Gamma and x-rays
are identical by nature and property but differ in the method by which they are produced. X-rays
are created extranuclearly by the conversion of the kinetic energy of electrons. Gamma rays, on
the other hand, are produced intranuclearly by the decay of radioactive isotopes [4]. These rays
have higher energy than x-rays and are more penetrating than beta rays. The penetration potential
of different forms of ionizing radiation is shown in Figure 1.1 [12].

Figure 1.1 Types of Radiation [12]. Different types of ionizing radiation have unique
properties and ability to penetrate different materials. Neutron, gamma, and x-rays are quite high
energy and very penetrating. On the other hand, alpha particles are large and heavy and can be
stopped by skin, a few inches of air, or a sheet of paper [12][14].

Ionizing radiation from radioactive decay can have a profound impact at the biomolecular
level, the principal effect being on deoxyribonucleic acid (DNA) [4]. It can either directly ionize
DNA, creating single (SSBs) and/or double strand breaks (DSBs) or can indirectly ionize DNA
through the creation of reactive oxygen species [4]. This is a major benefit for killing malignant
cells in cancer, but healthy tissue exposure to radiation can cause serious adverse effects. Mutations
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or cell death can result when DSBs are not correctly repaired by the cell, and this is a concern in
many radiotherapeutic treatments [15].

1.3

Novel Radiotherapeutic Medicine

As mentioned previously, ionizing radiation has a molecular impact on biological systems, and
this can be exploited to treat diseases such as cancer. In oncology there are a few different methods
by which radiation is administered. One method is by external beam radiotherapy, where radiation
is delivered to a tumor from outside of the body [16]. This treatment typically involves beta
particles or photons, and it can deliver large, precise doses to a specific tumor site. It can also be
used as a palliative for patients with metastatic disease [17].
Brachytherapy is another commonly utilized radiotherapy treatment, which involves the
placement of a radioactive source inside the body at the tumor site. This method offers the
advantage of a large radiation dose constricted to the site of the tumor, so the surrounding tissues
are largely spared [18]. Multi-catheter interstitial brachytherapy, in which catheters are implanted
into the tissue surrounding the tumor, has also regained popularity despite initially poor results
[18]. In breast cancer treatment, for example, patients reported few side effects, low recurrence,
and good cosmetic results. Despite this promise, brachytherapy is invasive and is still associated
with adverse side effects [19][20].
Finally, radioisotope therapy, where radiation is ingested or injected, is another area of
interest for novel therapeutic devices. Methods to direct radiation to tumor sites involve
conjugation to antibodies or peptides and also the natural movement of the radioisotope
biologically.
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Radioimmunotherapy is a segment of growing interest. In this treatment, a radiotracer is
conjugated to an antibody that recognizes an antigen overexpressed on cancer cells. There have
been various clinical trials including monoclonal, polyclonal, and engineered antibodies [21].
This type of treatment is particularly enticing for treatment of radiosensitive lymphomas and
leukemias, and clinical studies have shown that it is effective and well-tolerated [22]. Besides
radioimmunotherapy, many skeletal metastases can be treated by the biological localization of
radioisotopes. For example, specific radionuclides are bone seekers (32P, 89Sr, and 223Ra) and will
accumulate in areas of high bone turnover, such as bone metastases. Previously, most clinically
approved radioisotopes for treating these metastases were beta emitters, and this therapy was
palliative and limited by myelosuppression [23].
Alpha emitters have gained much attention in recent years, with the US Food and Drug
Administration (FDA) approving the first alpha particle therapy for cancer treatment in 2013 [25].
This therapeutic,

223Ra

dichloride (tradename Xofigo), was approved for the treatment of bone

metastatic prostate cancer and marked a major milestone in the field. Alpha therapy offers a few
distinct advantages over traditional radiotherapy. For one, the short range of alpha particles makes
damage to surrounding healthy tissue a less significant concern. Additionally, the high energy and
linear energy transfer of alpha particles make them very efficient at killing cells [26]. In
comparison to traditionally employed beta emitters, alpha particles have a shorter range of
penetration, leading to less toxicity and higher energy deposited per unit length (Figure 1.2) [23].
Targeted alpha therapy (TAT) is another emerging technique in the field. In TAT, alphaemitting radionuclides are targeted to a tumor site by a carrier, typically an antibody, and there are
many radionuclides under study for their potential in this therapy [27]. As an example, conjugated
225Ac

is currently in clinical trials for castration resistant prostate cancer and shows a promising
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antitumor effect [28].

213Bi

is also a promising candidate for TAT due to its lack of daughter

radionuclides and excellent chelation stability in blood plasma [27] [29]. This radionuclide has
been studied for multiple cancers including pancreatic, prostate, and small lung cell carcinoma
[30]. There are, however, some major limitations to TAT. The existence of diffusion barriers that
hinder tumor perfusion, the specificity of the antibody, the cost of the antibody, the amount of
unlabeled antibody, and the cost and availability of radionuclides are all among the issues that
hamper the further development of this treatment [31].

Figure 1.2 [24]. Alpha emitters have a few major advantages over beta emitters. They have
high linear energy transfer making them extremely cytotoxic. They are also confined more
tightly to the tumor microenvironment. On the other hand, beta emitters have a much longer path
length and have the potential to harm healthy tissue. They also have low linear energy transfer
and are not as cytotoxic to tumor cells.
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1.4 Regulatory Framework
The current debate over the proper way to regulate radiopharmaceuticals stems from their
unique properties in comparison to their non-radioactive counterparts. Presently, the FDA
regulates the use of radioisotopes in medicine, and it should be noted that the policies for
working with diagnostic and therapeutic radiopharmaceuticals differ. The Code of Federal
Regulations (CFR) Title 21 Parts 211 and 212 provide the rules and regulations for working with
radiopharmaceuticals. The regulations for diagnostic radioisotopes, particularly those used for
PET, are covered by Part 212, while therapeutic radioisotopes are covered by Part 211. In Part
211, radiotherapeutic drugs are considered the same as other ‘finished pharmaceuticals’ [32][33].
A recent review article in the Journal of Nuclear Medicine argues that the FDA should
create unique specifications for radiotherapeutics by partnering with the Society of Nuclear
Medicine and Molecular Imaging and the American College of Nuclear Medicine due to the
negligibly small masses involved in treatment and lack of experts in radiochemistry in the FDA
[34]. Table 1 and Table 2, both adopted from this article [34], demonstrate the very low dose of
radiopharmaceutical necessary for pharmacological effect in a typical patient (Table 1) and the
high number of heavy metals or impurities permissible in other common (non-radioactive)
pharmaceuticals (Table 2). This dichotomy between radiopharmaceuticals and other drugs
regulated by the FDA provides evidence for this side of the debate that radiotherapeutic drugs
should not be held to the same testing requirements.
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Table 1
Diagnostic Radiopharmaceuticals and Mass Typically Required for Single Dose Treatment

Diagnostic radiopharmaceutical

Mass

15

5.55 pg

O-H2O, 1,110 MBq (30 mCi)

18F-NaF,

370 MBq (10 mCi)

0.24 ng

18F-FDG,

370 MBq (10 mCi)

1.06 ng

13N-NH

370 MBq (10 mCi)

400–800 ng

3,

18F-florbetapir,

201Tl-chloride,

123I-NaI,

370 MBq (10 mCi)

Approx. 300 ng

111 MBq (3 mCi)

16.6 ng of 201Tl

14.8 MBq (400 μCi)

0.246 ng

Note. From “How Should the FDA Review Diagnostic Radiopharmaceuticals?” by Carol S.
Marcus, 2018, Journal of Nuclear Medicine, 59(6), p868,
(https://doi.org/10.2967/jnumed.117.200337).[34]
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Table 2
Permissible Impurities for Common Drugs as Approved by the FDA
Pharmaceutical

U.S. Pharmacopeia purity requirements

Acetaminophen (325-

May be up to 6.5 mg of unknowns in a 325-mg tablet. 3.25 μg of the tablet

mg tablet)

may be heavy metals.

Acetylsalicylic acid

May be up to 1.6 mg of unknowns in a 325-mg tablet. 3.25 μg of the tablet

(aspirin, 325-mg tablet)

may be heavy metals.
May be up to 0.25 mg of unknown chromatographic impurity per 50-mg

Atenolol (50-mg tablet)
tablet. May be up to 0.75 mg of nonchromatographic impurity.
Ascorbic acid (vitamin
May be up to 10 μg heavy metals per 500-mg tablet.
C, 500-mg tablet)
Rolaids (CaCO3, 675
May be up to 2.7 μg/tablet of heavy metals (lead being no more than 0.202
mg, and Mg(OH)2, 135
μg/tablet).
mg, per tablet)
Ibuprofen (200-mg
May be up to 4 μg of heavy metals per tablet.
tablet)
Note. From “How Should the FDA Review Diagnostic Radiopharmaceuticals?” by Carol S.
Marcus, 2018, Journal of Nuclear Medicine, 59(6), p868,
(https://doi.org/10.2967/jnumed.117.200337).[34]
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This side of the debate argues that testing radiopharmaceuticals to the same degree as
other drugs makes clinical trials and patient treatment too expensive, with no improvement to
drug safety [34]. The radiobiological expertise of members of the FDA who review these
pharmaceuticals is also called into question. However, there are other opinions on regulation that
deviate from this perspective. On the other side of the debate, experts believe that the price of
radiopharmaceutical development, while definitely higher than it was before FDA involvement,
is still significantly lower than that of other pharmaceuticals. For example, there is an
exploratory Investigational New Drug (IND) application for pharmaceuticals that are considered
a microdose (covered under USP 823), and this reduces the toxicology requirements [35]. They
further argue that the FDA has many trained professionals in radiology and that they work
closely with the nuclear medicine community. This side of the debate finally cites the importance
of the FDA in determining the safety and efficacy of drugs before clinical use [35].
This debate on how radiopharmaceuticals should be regulated is still as prominent today
as it was in the 1970s when the FDA gained oversight in the area of radiotherapeutic drugs. The
question of the overall toxicity of microdose drugs and the requirements that these drugs should
meet is still up for debate.

1.5

Motivations

Radionuclides have long been used to treat cancer, but there is emerging concern over the
regulations and quality control measures that these drugs must meet. In these methods, we aim to
create a robust quality control method for the evaluation of 223Ra and 227Th for their use
clinically. Current instrumentation for quality control is often not widely accessible, especially in
clinics. Additionally, other radionucleic impurities should be avoided clinically for patient health
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and environmental concerns. Our methods proposed here demonstrate the ability to distinguish
between 223Ra and 227Th and test each for radioisotopic purity on readily available
instrumentation. Our results show that these new methods can be used for quality assessment of
purity and composition and may provide insight into future drug development methods.
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Chapter 2: A Characterization Protocol for Quality
Control of 223Ra and 227Th

2.1 Introduction
Radionuclides have long been used as tools to image and treat cancer. When systemically
administered, specific radiopharmaceuticals may localize to sites of disease for diagnostic or
therapeutic purposes. There is a growing interest in alpha particle treatment for cancer because of
their radiobiological properties. 223RaCl2 (tradename Xofigo) is the first targeted alpha (𝛼)-particle
therapy approved by the FDA for treatment of men with bone metastatic castrate-resistant prostate
cancer [36]. Bone metastases are a clinically significant cause of morbidity and mortality in men
with prostate cancer [37]. As a mimetic of calcium, 223Ra is a bone-seeker, and it accumulates in
sites of active bone turnover, as exists in metastatic bone tumors [38][39]. The 𝛼 particles emitted
by 223Ra and its 4 𝛼-particle emitting daughters present a very short-track range, irradiating bone
metastatic prostate cancer cells and the surrounding tumor microenvironment, while largely
sparing healthy tissue from fatal, irreversible DNA damage. Additionally, the efficiency, safety,
and accessibility of

223Ra

in comparison to other radionuclides under study for castrate-resistant

prostate cancer make it an attractive potential therapeutic [40].
227Th

is also currently being studied for its potential in targeted 𝛼-particle therapy. This

radionuclide is the parent ion of

223Ra

and can be readily chelated and conjugated to various

targeting vectors (Figure 2.1) [41] [42]. This creates the potential to specifically target sites of soft
tissue and osseous metastases with molecular precision. Additionally, its relatively longer half-life
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allows certain advantages for preparation, transportation, administration and radiobiological effect
[43].
223Ra

and

227Th

are typically produced from an

227Ac

(21.7 year half-life) source and

purified using an ionic-exchange resin. Radionuclidic purity is often evaluated by gamma
spectroscopy [44]. However, the assortment of daughters emitted through concatenated decay of
these radionuclides leads to a complicated characterization essential for reliable quality control of
these radiopharmaceutical products. In addition, the complex (gamma ray, beta, and alpha particle)
decay profiles of

227

Th and

223

Ra have overlapping emission spectra, further complicating

individual radionuclide distinction using available quality control instrumentation [45].
There is much debate surrounding the appropriate regulation of radiopharmaceuticals.
These drugs are given in infinitely small masses, and typically, patients receive only a single
treatment [34]. These doses are considerably smaller than those of conventional drugs, and for this
reason, the FDA has a unique set of regulations for screening that cover the first-in-man translation
and routine clinical use of radiopharmaceuticals by way of a microdose exploratory Investigational
New Drug (IND) application [35].
A key consideration for the field is how to properly validate novel radiopharmaceuticals
for clinical applications. Our work shows that there are available technologies that are suitable for
demonstrating the quality of these radionuclides, which may be translated over to clinical
applications, such as testing the quality of radiolabeled antibodies or peptides.
Here, we undertook a series of characterizations on technologies typically accessible for
radiopharmaceutical identification and determination of purity, including radio-Thin Layer
Chromaography (TLC) readings, gamma counting, and alpha detecting solid-state semiconductor
measurements. Through these methods, we were able to develop a robust quality control
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characterization protocol for a 227Th-radiolabeled antibody construct. We demonstrated 227Th and
223Ra

identification and quantification utilizing gamma spectrometry and gamma counting. These

measurements were cross-checked by way of an alpha imaging spectrometer. A novel setting
utilizing a radio-TLC scanner was tested to specifically detect alpha-emitting radionuclides and
daughters by changing the high voltage of the instrument (Further details concerning the
specifications of each instrument is provided in Table 3). Our methods here develop a quality
control protocol enabling therapeutic radionuclide identification and characterization.

Table 3
Specifications for Instrumentation Examined in these Methods
Bioscan – 1500 V
Detected Radiation All ionizing radiation

Bioscan – 1000 V

Gamma Counter

Minipix

Alphas

Gammas

All ionizing
radiation

Detection
Mechanism

P-10 ionizing gas

P-10 ionizing gas

Well-type NaI
detector

Si solid-state
semi-conductor
(256 x 256 pixels)

Detection Time*

1 minute

5 minutes

1 minute

15 minutes

Detection Resolution
[46][47][48]

3 mm‡

3 mm‡

< 30%‡

Spatial: 9 lp/mm
Energy: 0.8 keV
(THL) and 2 keV
(ToT)

Software

WinScan

WinScan

Wizard2 Data
Analyzer

PixetPRO

Portable

No

No

No

Yes

*

For samples > 0.025 𝜇Ci
most gamma emitters

‡ For
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Dowex 1x8

Figure 2.1. (A) Decay chain of 227Th, which into 223Ra. (B) Depiction of the anion exchange column used
for the purification of 223Ra and 227Th. (C) Antibody radiolabeling with 227Th. 227Th is chelated to an
antibody and purified using size exclusion chromatography.
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2.2 Materials and Methods
All reagents and solvents used in these methods were purchased from Sigma-Aldrich,
unless otherwise noted.

227 Th

was supplied by the Department of Energy. All buffered solutions

were prepared from metal-free water purified using Chelex 100 resin (BioRad).

2.2.1. Purification of 223Ra and 227Th
227

Th and

223

Ra were purified from a

227

Th source using a microgenerator column as

previously described [49]. Briefly, an anion exchange Dowex 1x8 chloride form resin (100-200
mesh) was first conditioned with deionized water to remove any residual fine particulates. The gel
was then exercised with both a caustic (1N NaOH) and acidic (1N NaCl/0.05N HCl) wash. The
final processed resin was stored in 50 mL of 20% ethanol prior to isotopic purification.
A Poly-Prep polypropylene empty column scaffold (BioRad) was then filled with 2 mL of
the processed resin forming the microgenerator column. The column was washed with 3 column
volumes of metal-free water and 3 column volumes of 80% CH3OH:20% HNO3 (2N). The source
was loaded on the column in a solution of 80% CH3OH:20% HNO3 (2N) with a loading volume
less than 10 % column volume. 223Ra was first eluted with 80% CH3OH:20% HNO3 (2N) in 5 mL
fractions. The activity of each eluted fraction was measured on a dose calibrator (CRC-15 Pet;
Capintec Inc.) using a calibration setting predefined using a National Institute of Standards and
Technology (NIST)

223Ra

standard, until no more radioactivity was measured. At this point, the

mobile phase was switched to HCl (2N) to elute 227Th from the column in a single 5 mL fraction.
The activity remaining on the column was measured using the dose calibrator (using a predefined
calibration number) to determine if all of the 227Th had been eluted from the column or if further
elution was required for recovery.
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Immediately following purification, radionuclidic purity was evaluated. The activity per
fraction was measured using the dose calibrator and the purity assessed using gamma spectrometry
with a high purity Germanium (HPGe) detector (GEM-50195-S; Ortec), enclosed in a 10 cm lead
shield (HPLBS1, Ametek). A 1 mL Eppendorf tube with 100 𝜇L of a fraction was placed at a
standardized distance from the detector and measured for approximately 10 minutes. Spectral
acquisitions were acquired and analyzed by Gamma-Vision Software (version 8.0, Ametek).

2.2.2. Characterization of 223Ra and 227Th using radio-TLC
The Bioscan AR-2000 Imaging Scanner (Eckert and Ziegler Radiopharma, Inc.) was used
to measure the decay of
Triplicate of purified

223Ra, 227Th,

223Ra

and a mixture of both isotopes over a completed half-life.

(0.025-0.1 𝜇Ci, 2-5 𝜇L) was spotted on 2.5 cm x 2.5 cm squares of

Whatman chromatography paper (3 mm thick, Schleicher and Schuell). A similar process was
conducted for pure 227Th and a mixture of a known amount of 223Ra/227Th. Each paper strip was
covered in cellophane wrap (GLAD ClingWrap; The Clorox Company) and read on the Bioscan
AR-2000 Imaging Scanner for 1 minute at a high voltage setting (1500 V) and for 5 minutes at a
low voltage setting (1000 V). Placing each square at a similar position on the scanner, these
measurements were completed daily covering an entire half-life of 223Ra (11.4 days) or 227Th (18.7
days).
The counts per minute (CPM) over distance data was exported from the Bioscan software
(v 3.13), and the total area under the curve was calculated using Riemann sums for each time point.
The averaged sum was plotted, and plots were fitted under a one-phase decay curve.
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2.2.3. Quantitative readings of 223Ra and 227Th using Gamma Counting
The Wizard2 Gamma Counter (PerkinElmer) was used to measure the decay of
227Th

223Ra

and

over an entire half-life. Briefly, purified 223Ra, 227Th, and a mix were spotted on each of 3 1

cm x 1 cm squares of 3 mm chromatography Whatman paper (cat no. 3030 917). Each paper was
then inserted into a 12 x 75 mm disposable culture tube (VWR), and each tube was read on the
gamma counter for 60 seconds daily over the period of one entire half-life. The samples were
counted on an open channel covering the full energy window from 100 to 2000 keV. Each sample
was counted for 60 seconds. The first measurement was completed on day 0, approximately 1 to
3 hours post-isotopic purification.
For quantification of activity amounts, the gamma well-counter and HPGe system were
calibrated using a NIST traceable standard of 223Ra. Volumes of the standard were aliquoted into
12 mm x 75 mm polypropylene tubes in order to form a dilution series, and each volume of the
solution was weighed using a precision microbalance for accuracy (XP205, Mettler Toledo).
Initially the standards ranged from 0-9 kBq, and the full spectrum of gamma emissions was
captured by 2048 (gamma counter). Counts per minute were plotted over activity amount, and
linearity at each measured time point was approximately r 2 = 0.992. The same undertaking was
achieved using quantitative HPGe measurements using the 154 keV spectral line for

223Ra,

producing a linear response of r2 = 0.997.
A method was developed to separate 223Ra and 227Th activity amounts using the automated
sample-changing gamma counter (Figure 2.2). Spectral measurements of

223Ra

(at secular

equilibrium with its daughters) and freshly purified 227Th (<10 min, to avoid significant daughter
contributions) were gathered each day over a period of 25 days following radioisotopic separation,
providing time for in-growth of daughter and attendant emissions. Quantitation of the 227Th portion
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to absolute (Bq) activity amounts was made using the absolute NIST-quantification of the

223Ra

component and the known relative amounts of each in the mixed spectra calculated using the
Bateman equations [50].

days
days
days

days
days
days

days
days

days
days

days
days
days
days

days
days

Figure 2.2. Automated Gamma Counter Spectral Measurements. A) NIST calibrated
dilution series for 223Ra standards. B) Quantitation of activity from traceable source summed
across channels. C) Measurements of 223Ra at equilibrium over time, days indicated. D)
Measurements of 227Th over time. Ingrowth of 223Ra and daughters is noted.
Taken together, these measurements allowed two basis functions (for 227Th and 223Ra with
daughters) to be defined, each in units of ‘counts per spectral bin per Bq’. The basis function
(Equation 1) is solved by initializing w1 and w2 to arbitrary positive values.
𝑤𝑘 = 𝑤𝑘 ∙ ∑𝐽𝑗=1 ∑𝐼

𝑆𝑗

𝑖=1 𝑤𝑖 𝐵𝑖𝑗

(1)

Here, I=2 and J is the number of bins in the spectral measurement. The Sj’s contain the
spectral measurements of a mixed sample of 227Th and 223Ra (in units of counts per bin), where the
latter is assumed to be in secular equilibrium with its daughters. If B1 is the basis function for 227Th
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and B2 is the basis function for 223Ra (and its daughters), the resultant values for w1 and w2 are the
Becquerel amounts for 227Th and 223Ra with its daughters, respectively, assuming the units of B1j
and B2j are counts per bin per Bq. As a note, the Bq amount of 223Ra can either refer to 223Ra alone
(and therefore also to each of its daughters) or to the sum of the radioactivity for 223Ra plus all of
its daughters, depending upon how the units of B2 were defined. The expression is iterated until
convergence is reached.

2.2.4. 223Ra and 227Th readings using Minipix, alpha spectral detection
The Minipix portable small USB spectral imaging camera (ADVACAM) was used to
characterize the alpha decay of

223Ra

and

227Th

over one entire half-life. The Minipix, shown in

Figure 2.3, is a miniaturized radiation camera that contains a single Timepix device with a silicon
sensor. It is able to distinguish between different ionizing particles based on their tracks and is also
capable of measuring the energy of each detected particle, making it a useful tool for monitoring
ionizing radiation over time. Approximately 0.025 𝜇Ci of purified 223Ra or 227Th was spotted on
a 3 cm x 3 cm squares of 3 mm chromatography Whatman paper. The clustering tool on the PIXET
PRO software (ADVACAM, v. 1.4.10.704) was used to collect the global cluster volume of each
energy cluster. This could then be interpreted as the energies of the alpha particles present in the
sample. To calibrate the instrument, sources of alpha-emitters were acquired, and the bias was
adjusted accordingly so that the energies of the alpha particles of each radionuclide were
standardized. The two sources used for calibration were a
and a

241Am/237Np/244Cm

210Po

source (Spectrum Techniques)

source (Eckert and Ziegler). For the measurement of

223Ra

and

277Th
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alpha decay, the source was placed on top of the alpha particle imaging spectrometer,
approximately 0.7 cm from the detector, and measured daily over the period of one half-life with
the clustering tool set to collect 7000 frames (approximately 15 minutes). The data was exported
from the PIXET PRO software system and graphed as counts measured at each energy (keV) using
Graphpad Prism.
Figure 2.3. The Minipix Portable USB Spectral Imaging Camera

2.2.5. Radionuclide separation using DGA Impregnated Chromatographic Paper
A mixture of 227Th (0.012 𝜇Ci) and 223Ra (0.007 𝜇Ci) was spotted on a 100 mm x 10 mm
strip of N,N,N’,N’-tetra-n-octyldiglycolamide (DGA) impregnated chromatography paper
(TrisKem International) and migrated with 1 M HNO3 as the mobile phase. The migrated strip was
read using the Bioscan AR-2000 Imaging Scanner at a high voltage setting both of both 1500 V
and 1000 V. It was measured 5 min, 1 hour, and 3 hours post-migration, with an acquisition time
of 5 minutes at 1500 V and 10 minutes at 1000 V. A second identical DGA migration was cut into
3 equal sections and measured on the HPGe detector immediately following separation for
radioisotopic identification.

23
2.2.6. Radiolabeling Antibodies with 227Th
An antibody conjugated to a

227Th

chelator was prepared and purified by size exclusion

spin centrifugation (manuscript in progress). The construct prepared in these methods was
ofatumumab, an anti-CD20 human monoclonal antibody [51]. The unpurified material quality
control was compared to that of the purified material following the same steps previously described
(2.2.2; 2.2.3;2.2.4).
The purified and unpurified samples of the

227Th-labelled

antibodies were spotted in

triplicate on silica chromatographic paper and migrated in a mobile phase of Diethylenetriamine
pentaacetate (DTPA). Following migration, both sets of strips were imaged on the Bioscan AR2000 imaging scanner at a high voltage setting of both 1000 V and 1500 V. Following, the strips
were cut in half (at 50 mm), and both sets were measured on the alpha particle imaging
spectrometer. Each half was then measured on the gamma counter on an open channel covering
the full energy window from 100 to 2000 keV for 60 seconds each.

2.3 Results
Our goal is to develop quality control methods for targeted alpha particle therapy
constructs. The radioactive sources were purified using a previously described microgenerator
column to produce 227Th and 223Ra [48]. Radioisotopic purity was checked using the HPGe (Figure
2.4). Although the HPGe is a simple method for quality control and

227Th

and

223Ra

are easily

distinguished, many community care centers and hospitals do not routinely use such equipment.
We therefore tested more readily available technologies that are used for quality control measures
in nuclear radiopharmacy.
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Figure 2.4: HPGE Assessment of Sources. HPGe assessment of 227Th (A), 223Ra (B), and a mix (C). (A) 227Th
describes the energy peak read. (B) The HPGe spectrum of 223Ra, showing high purity. The HPGe was also used
to assess the silica DGA strip spotted with a mix of 227Th and 223Ra and migrated in a mobile phase of 1 M
HNO3 (D, E, F). The bottom of the strip showed unmigrated 227Th (D) and the top of the strip showed pure 223Ra
(F). The middle of the strip had much lower counts at the time of reading but showed 211Bi as the primary
isotope present (E).

2.3.1. i-TLC imaging scanner
We here examined the differences in measurement between the default setting of 1500 V
and 1000 V for 227Th and 223Ra. A 227Th source that was measured over a completed half-life (18.7
days) at 1500 V on the scanner showed an increase in CPM over time, gradually stagnating in
slope as the half-life was neared (Figure 2.5A). As a complex emitter, the increase in CPM over
time can be attributed to the ingrowth of the daughter isotopes, specifically

223Ra,

which presents
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a comparable half-life and strong emitted gamma rays (324 keV, 3.64%; 269 keV, 13.30%; 154
keV, 6.02%; 144 keV, 3.47%).
Measured under similar parameters,

223Ra

showed a profile moderately fitted over a

standard one-phase decay (r2 = 0.5810) (Figure 2.5B). This weak fit is most likely due to the
ingrowth of the daughters of 223Ra, as the i-TLC cannot distinguish between the emissions of these
radionuclides. We were therefore curious to see if this weak fit would still be present when the
high voltage setting was set to 1000 V.
The mix of 227Th and 223Ra produced a fitted line with minimal changes in CPM over the
half-life of 227Th (Figure 2.5C), again demonstrating the limitations of the system in measuring the
isotope mix.
At lower bias voltage, beta particles will not produce detectable signal, while higher energy
alpha particles will continue to produce electrons for signal amplification. Switching to 1000 V
permitted alpha particle specific readings (Figure 2.5D-F). The resolution at this lower-voltage
setting was enhanced, yet a longer acquisition time was needed to acquire reliable counts.
Although, the observed curve profiles were similar between 1000 V and 1500 V for the mix of
227Th/ 223Ra

and for

227Th

alone, the count plots for

223Ra

matched a more accurate one-phase

decay despite the presence of daughters (R2 = 0.8611). This is likely due to a better recognition of
alpha emission under the low-voltage setting when working in the presence of limited emitting
isotopes (all 223Ra progenies present a short half-life with limited contribution over a window of
24 h). These observations suggest the utility of measuring radioisotopes under different high
voltage settings and also demonstrate that the observed counts for a radioisotope that decays to
radionuclide daughters will be inflated by this measurement system.

26

B.

A.

C.

6000

6000

4000

4000

CPM

CPM

CPM

6000

2000

2000

2000

0

0

0
0

5

10

15

20

0

25

5

10

0

15

5

15

20

25

20

25

F.

E.

1000

800

800

CPM

600

CPM

10

Time (days)

Time (days)

Time (days)

D.

4000

400
200

600
400
200
0

0
0

5

10

Time (days)

15

0

5

10

15

Time (days)

Figure 2.5. Readings at 1500 V for (A-C) and at 1000 V (D-F) of each radioisotope and mix source spotted on
cellulose support, measured over completed half-life: (A, D) 227Th counts per minute were plotted and fit according
to a one-phase exponential decay. (B, E) 223Ra CPM were plotted and fit to a one-phase exponential decay. (C, F)
Mixed source of 223Ra and 227Th. For all curves, the initial point is excluded from the exponential fitting to allow the
system to reach equilibrium.
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We tested the same instrument utilizing a migration of

223Ra/227Th

on DGA impregnated

thin layer chromatography paper to separate 227Th from 223Ra based on ionic discrimination. These
TLC strips were measured on the scanner. Immediately following migration, three distinct peaks
were recorded at the 1500 V setting (Figure 2.6A), while two peaks were present when measured
at the high voltage setting of 1000 V (Figure 2.6D). Approximately one hour later, the middle peak
had decreased significantly (Figures 2.6B, 2.6E). By three hours post-migration, the middle peak
disappeared (Figures 2.6C, 2.6F). The top and bottom peaks of the strip were not observed to
decrease over time. In order to verify the radioisotopic identity for each peak, a second strip was
migrated, and each section was measured using the HPGe (Figure 5D, 5E, 5F). These
measurements suggested that 227Th (4+ charge) was present at the bottom of the strip,
charge) migrated to the top, and
middle of the strip.

211Bi

223Ra

(2+

(3+ charge) (half-life = 2.14 minutes) was present in the
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Figure 2.6. A strip of DGA-coated chromatographic iTLC paper was spotted with a mix of 223Ra /227Th at 10 mm
and migrated with a mobile phase of 1 M HNO3 up to 100 mm. TLC readings over high voltage 1500 V at 20 min
(A); 1h (B); and 3h post-migration (C). TLC readings of the same mix at 1000 V at 5 min (D); 1 h (E); 3 h postmigration (F). The middle peak seen at both high voltage settings immediately following purification gradually
decreases until it completely disappears 3 hours post-migration.

29

2.3.2. Sodium Iodide Gamma Counting
Another widely available instrument for radiopharmaceutical quality control is the gamma
counter. Although capable of gamma emissions detection with outstanding accuracy, distinction
of

227

Th and

223

Ra is challenging due to characteristic energy emissions that are too close for

accurate detection (Figure 2.7A). Indeed, the CPM acquired over a full window of energy spectra
(100-2000 KeV) for 227Th and 223Ra presents similar measurement profiles to those acquired under
the radio-iTLC scanner (Figures 2.8A, 2.8B). The mix of the two radioisotopes on the gamma
counter shows a trend that is similar to that of
227Th

227Th,

due to the higher amount of activity from

than 223Ra that was spotted on the strip initially (Figure 2.8C).
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Figure 2.7: Gamma counter assessment showing the spectra of a mix of 227Th and 223Ra (A) and the
unmixed spectra of pure 227Th and pure 223Ra (B) determined from our developed algorithm.

Here, we have developed a novel method utilizing mathematical metrics to deconvolute
227Th

from the 223Ra spectra translating counts into accurate absolute radioactive characterization

per radionuclide identification. Utilizing this method coupled with gamma counting, the spectra of
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227Th

and

223Ra

can then be un-mixed, yielding an absolute quantification of each radionuclide

(Figure 2.7B).
Pure 227Th plots demonstrated a one-phase decay curve (r2 = 0.9980) with high accuracy
while recording the ingrowth of 223Ra over the course of one half-life (Figure 2.8D).
Pure

223Ra

similarly reveals predicted accurate one-phase decay (r2 = 0.9993) with no

significant amount of 227Th detected (Figure 2.8E).
The mix of

227Th

and

223Ra

showed the expected exponential decay for

227Th

as well as

223

Ra ingrowth (227Th: r2 = 0.9294) (Figure 2.8F).
Comparing 3 different qualities of samples (pure

227Th,

pure

223Ra

and a mix of both

isotopes) demonstrated the capability of the described gamma counting method to accurately and
reliably identify and quantify 223Ra and 227Th when mixed.
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Figure 2.8. Gamma counting readings. Total CPM acquired in open window channel measured for 227Th
(A), 223Ra (B) and the mix (C); Deconvoluted Activity (Bq) calculated for a pure 227Th sample (D) showing
227Th decay and 223Ra in-growth fitting a single-phase decay (R2 = 0.9980). (E) Activity (Bq) for 223Ra fit with
a single-phase decay (R2 = 0.9986). (F) 227Th and 223Ra sample mix activity (Bq) plot.
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2.3.3. Minipix: Alpha Spectral Detection
Characterization of radiopharmaceuticals by particle emissions rather than gamma rays is
also possible.

227Th

and

223Ra

emit alpha particles at unique non-overlapping energies, and we

were interested to measure these using the Minipix spectral imaging camera. This inexpensive and
easy-to-use solid-state semiconductor camera is of great interest for the purpose of alpha emitting
isotope differentiation. Our goal here was to compare spectral images acquired for each isotope
and then distinguish between them. There was significant spreading of individual peaks when
measuring both

227

Th and

particles emitted by

223

Ra (Figure 2.9). We attributed this to the high number of alpha

223Ra, 227 Th,

and their daughters. We also did not collimate the system, as

collimation produced no significant reduction in spreading of individual peaks. We were therefore
unable to detect individual particle spectra.
Distinguishable differences are noted, however, both over time for each radionuclide and
when compared to each other (Figure 2.9D). 223Ra shows two very spread peaks at approximately
5500 and 7500 keV (Figure 2.9B). The peak seen at 5500 keV corresponds to the alpha particles
that are released by 223Ra, which itself does not emit alphas with energy over 6000 keV (Table 4).
These higher energy alphas are most likely contributed by the daughters of 223Ra as it decays over
time, specifically

215Po

(7386.1 keV) and

210Po

(7450.3 keV) (Table 4). Over the course of one

half-life, total counts in the 223Ra sample decrease by approximately one half (Figure 2.9F).
Unlike 223Ra, pure 227Th shows only one distinct peak at around 5500 keV (Figure 2.9C).
Over time, the counts of this peak increase (Figure 2.9E), due to the ingrowth of 223Ra, which emits
alphas at a very similar energy to 227Th (Table 4). There is also the emergence of a second peak at
around 7500 keV, again corresponding to the high energy alphas emitted by the daughters of 223Ra.
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We conclude from these results that it is possible to distinguish between 227Th and 223Ra using the
alpha particle spectrometer.
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Figure 2.9: Alpha Particle Detection using the Minipix Spectral Imaging Camera
(A) 241Am/237Np/244Cm standard source read using Minipix spectral imaging camera. From left to right, the
three peaks correspond to the alpha particles emitted by 237Np, 241Am, and 244Cm. (B,C) 223Ra (B) and 227Th (C)
imaging spectra over one complete half-life. (D) For the mixed spectra, the day 0 measurements of the pure
radionuclides from B and C were normalized and plotted together. (E, F) Plotted counts acquired at 5.43 meV
and 7.45 meV for pure 227Th (E) and 223Ra (F). 5.43 meV depicts the most significant alpha particle contribution
emitted by 223Ra, and 7.45 meV corresponds to the alpha particle released by 211Po and relates to the second peak
seen in the graphs. Both increase over time for 227Th and decrease for 223Ra.
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Table 4
Most significant alpha particle energies (Intensity > 3%) of the radioisotopes in the decay chain
of 227Th. All energies are recorded in keV
227Th

223Ra

219Rn

211Bi

215Po

211Po

5700.8

5433.6

6425.0

6278.2

7386.1

7450.3

5708.8

5539.8

6552.6

6622.9

5713.2

5606.7

6819.1

5756.9

5716.2

5866.6

5747.0

5959.7
5977.7
6008.8
6038.0

2.3.4. Application to 227Th-radiolabeled antibody characterization

Finally, we applied the previously presented QC techniques to the characterization of a
227Th-radiolabeled

antibody construct. We tested these methods with purified and non-purified

antibody material. Following migration on silica-coated chromatography paper, strips were
measured on the radio-TLC. The antibody exhibited similar patterns at both high voltage settings
of 1000 V and 1500 V. For the purified sample, only a single peak at the bottom of the strip was
read, while the unpurified presented 2 peaks, suggesting the presence of free radioisotopes (Figures
2.10A, 2.10B, 2.10E, 2.10F).
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We next measured the

227Th-radiolabeled

The purified antibody showed only

227Th,

antibody using our gamma counting protocol.

which was present primarily at the bottom of the TLC

strip; this contrasts to the unpurified material, which showed a significant amount of

223Ra

migrated to the top of the strip (Figures 2.10C, 2.10G).
When read on the Minipix spectral imaging camera, the purified sample depicts

227Th

at

the bottom of the strip, while detecting nothing at the front, and the unpurified sample showed
223Ra

at the front of the strip (Figures 2.10D, 2.10H).
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Figure 2.10: 227Th-labeled antibody migrated on silica-coated chromatographic iTLC with DTPA (10 mM).
Purified and non-purified material were compared using radio-TLC scanner (A,B,E,F), gamma counting
(C,G), and alpha spectral imaging camera (D, H). The TLC scanner of purified and non-purified 227Thlabeled antibody was acquired immediately after migration at a high voltage setting of 1000 V (A, E) and
1500 V (B, F), showing a main peak at the spotted area characteristic of 227Th labeled material and
migration of unchelated 223Ra at the top of the strip. (C, G) Purified (C) and unpurified (G) 227Th-labeled
antibody measured using gamma counting. 227Th was found primarily non-migrated at the bottom of the
strip, confirming protein labeling. 223Ra was detected at the top of the strip for the unpurified material (G);
(D, H) Alpha spectral imaging of the purified (D) and non-purified (H) 227Th-labeled antibody showed 227Th
alpha emission at the bottom of the strip for both materials and 223Ra contribution at the top of the strip for
the non-purified material.
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2.4 Discussion
The ability to accurately and expeditiously differentiate between a radiolabeled
pharmaceutical and daughter radionuclides is of emerging importance in the development of new
radiopharmaceuticals that require quality control for clinical use. The state-of-the-art quality
control of radiopharmaceuticals has been well-developed over the course of the last 50 years and
is especially suited for the detection of single gamma emitting isotopes for imaging tracers.
However, with the increasing interest and progress in the field of radiopharmaceuticals for
therapeutic use, the classic instrumentation utilized for radiotracer detection appears to be of
limited efficiency to detect a radioisotopic mix or alpha-emitting isotopes.
For the example of 227Th labeled antibodies, our results demonstrate the ability to correctly
discriminate

227Th

and

223Ra

utilizing commonly available technologies, such as an ionizing gas

proportional chamber or a gamma counter. We further show the practical applications of these
methods to the field for the quality assessment of radiolabeled antibodies.
One common quality control approach used for radiopharmaceutical evaluation is TLC
migration read using a P-10 gas imaging scanner. Typically, the scanner is utilized for radioactive
detection on instantaneous chromatographic migration on a thin paper strip. The system relies on
a P-10 gas source, which ionizes in the presence of ionizing radiation and creates a pulse of
electrons that is proportional to the amount of activity present in the sample. The system is by
default run at a setting of 1500 V for detecting ionizing radiation. Our results show that at 1500 V,
the imaging scanner presents low accuracy for measuring these complex emitters. The measured
decay of 223Ra is not an exact exponential decay, with an r2 of only 0.5810, demonstrating that this
setting is unfit to measure complex alpha-emitting isotopes and mixtures. We believe that this
discrepancy can be explained by the presence of the daughters of 223Ra on the support, which also
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emit different forms of ionizing radiation. The same observation is noted for pure

227 Th,

which

also did not follow a one-phase decay. The increase in CPM over time demonstrates that the
radiation released by the in-growth of 223Ra and its daughter radionuclides have a higher ionizing
effect on the P-10 gas source.
When lowering the high voltage setting to 1000 V, we found that the accuracy of
measurement increased for 223Ra. The r2 value increased to 0.8611. The most likely reason behind
this observation is that the alpha particles emitted during the decay of 223Ra have a higher ionizing
effect on the P-10 gas than its daughters. The accuracy of

227

Th and the mix of the two

radionuclides demonstrated a comparable fitted curve at both high voltage settings.
When the imaging scanner was used to measure a mix of

227Th

and

223Ra

migrated on a

DGA impregnated strip at a setting of 1500 or 1000 V different migration profiles were recorded.
At 1500 V, 3 peaks were identified, suggesting the separation of each ion species on the
chromatographic strip with

227Th

unmigrated at the origin,

211Bi

in the middle, and

223Ra

at the

front. Identities were all confirmed by HPGe measurement. Readings at 1000 V demonstrated
higher resolution for the acquisition of

227 Th

and

223Ra

peaks. Interestingly,

227Th

measured at

1000 V presents higher absolute counts compared to the 1500 V setting. At this setting, the 227Th
showed a higher CPM than that of 223Ra, while the opposite pattern was recorded at 1500 V. Both
settings demonstrated the disappearance of 211Bi after 3 hours, which was expected. We therefore
concluded that although a longer acquisition time is necessary, the high voltage setting of 1000 V
does indeed have a higher resolution and detects alpha particle emission.
Gamma counting readings under an open energy window setting (100-2000 Kev) showed
similar results to those of the radio-TLC. However, 223Ra recordings demonstrated a more accurate
one-phase decay of the plotted counts, with an r2 of 0.9993. This shows a definite increase in
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accuracy for these sources when read on the gamma counter over time compared to the Bioscan
imaging scanner. This could be explained by the single gamma emission of 223Ra identified by the
gamma counter with the negligible interfering contribution of the daughters and their short-halflives.
Our developed deconvolution method enhanced the precision of the gamma counter
enabling the distinction of 227Th from 223Ra in the same measurement. The gamma energy spectra
of 227Th and 223Ra share significant regions of overlapping energies and are therefore challenging
to distinguish. Measurements of each pure radioisotope presented exceptional one-phase decay,
with an r2 value over 0.99 for both 227Th and 223Ra sources over the course of one entire half-life.
Both the mix and pure 227Th show the ingrowth of 223Ra, with linear increase of 223Ra. The absolute
activity values first begin to plateau around 10 days post purification. This is consistent with the
transient equilibrium data, which is reached at approximately 19 days.
Overall, these results show exceptional accuracy of the gamma counter measurements to
distinguish 227Th and 223Ra. This result is mostly explained by the fairly separate gamma emission
of each isotope observed by taking one energy channel at a time and deconvoluting each using the
algorithmic method generated from the 223Ra NIST standards calibration.
This innovative method can be applied in research or clinical settings to get a quantitative
assessment of purity and the exact activity of each isotope in a supposed mixture of
223Ra.

227Th

and

The present method for testing Xofigo®, is by high resolution gamma counting [52]. This

method is unable to define specific radionuclide purity, so it is recommended that a limit for any
unknown gamma impurities or for the parent isotope 227Ac are set. Our methods will be useful for
these clinical gamma counting applications, as the spectra of 227Th and 223Ra can be very difficult
to discriminate.
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As an alternative analytical method for measuring the emitted alphas from 227Th and 223Ra,
detection using a solid-state semi-conductor was investigated. Our results show that this method
was able to differentiate

227Th

and

223Ra.

There was significant spreading of the peaks for

227Th

and 223Ra, which can be attributed to the plethora of alphas of different energies released by the
radioisotopes and their daughters between 5-8 meV as well as the distance that the alphas had to
travel through the air before reaching the detector (0.7 cm). Yet, the two radioisotopes could still
be discriminated. Pure

227Th

demonstrates a single peak close to 6000 keV, which is consistent

with the radiated alphas. Over time, this peak shifts slightly to the left and increases as 223Ra grows
into the mixture, and a second peak closer to 8000 keV appears as well. Alphas released at such
high energy are the result of the emitted alpha particles from the daughters of

223Ra.

These

characteristics become obvious in the spectra in as little as a day post-purification, presenting the
accuracy of this method for showing pure 227Th as opposed to that which has some ingrown 223Ra.
Pure 223Ra when measured over time shows both peaks previously mentioned in the 227Th spectra,
with the lower one corresponding to

223Ra

and the upper to its high alpha energy daughters. As

expected with the decay, both peaks decrease in overall counts in the course of one half-life to
approximately half of the day 0 measurement. As demonstrated here, it is possible to quantitatively
measure and distinguish 227Th and 223Ra using a solid-state semi-conductor to measure the alpha
particles.
Finally, we showed the practicality of these methods using a 227Th-labelled antibody. Our
results clearly show the ability to distinguish between the pure construct and the non-purified one
utilizing all 3 previously described methods. The radio-TLC at both high voltage settings clearly
exhibited the presence of two peaks in the sample, which was not purified, while the purified
sample only shows one unmigrated spot. This demonstrates the presence of two chemically
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different species, but we were unable to identify individual radioisotopes by Bioscan acquisition.
To achieve further identification, we measured the samples using the gamma counter and
processed the counts per channel of energy using our deconvolution algorithmic method and were
successfully able to differentiate between

227Th

and

223Ra,

demonstrating that the impurity that

migrated to the top of the strip was attributed to free 223Ra.
This is an important addition to the field as it shows the validation of this method to quickly
and accurately determine the purity of a prepared radio-drug. To further demonstrate the
importance of these results, we tested each section of the pure and impure sample on the alpha
spectrometer. Again, our results show the ability to distinguish between the spectra of
223Ra. Only 227 Th is present

227Th

and

in the pure sample, based on the spectra with the single peak. However,

the results from the impure sample show two distinct spectra for the front and base of the strip,
with the front showing 223Ra and the base displaying 227Th. These results validate that these quality
control methods can both qualify and quantify the presence of 227Th and 223Ra in the same sample,
which is significant progress contributing to advancement for the field.
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Chapter 3: Summary and Future Directions
Overall, these results fill an important gap with respect to quality control for
223Ra

227Th

and

for research and clinical purposes. Our data demonstrates accessible and accurate methods

for assessing this distinction, which can be translated clinically as more radiopharmaceuticals are
developed for cancer treatment. Future research efforts will be necessary to calibrate
223Ra

227Th

and

in a mixed setting, but our information is an important starting point for an area that is

continuing to grow. Future work will focus on the evaluation of additional constructs and labeling
techniques using these quality control methods.
The methods described here provide an important framework for radiopharmaceutical
quality control for other complex emitters, which is an important step for advancement in the field.
Future studies should further examine radioisotopes that have many daughters to expand
knowledge on how to best characterize these more complex ions. Specifically, a characterization
of the longer half-life parent of 227Th, 227Ac, would be useful for further quality assurance of these
emerging alpha-emitting therapeutics. Our developed deconvolution algorithm can also be
incorporated into the field of nuclear medicine to distinguish between the gamma spectra of other
radioisotopes that have overlapping spectra, an important step in quality control for developing
pharmaceuticals. Additionally, the utility of these methods should be tested on other radiolabeled
conjugates to justify the universality of the results. Finally, as an emerging technology, the
applications for the Minipix spectral imaging camera for the field should be considered. It is
possible to distinguish between different forms of ionizing radiation, which could be very useful
to determine content and quality of a sample quickly and accurately. It would also be interesting
to test the accuracy of the alpha imaging camera in measuring the half-lives of radioisotopes, as
we demonstrated on the gamma counter and radio-TLC for 227Th and 223Ra.
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In conclusion, the work presented here has important implications for quality control of
radiopharmaceuticals for the nuclear medicine community. Specifically evaluating
223Ra,

227Th

and

two novel, emerging radionuclides for alpha therapy treatment, demonstrates the possibility

for a higher degree of quality assurance even for complex emitting radionuclides. Importantly,
these results can be translated for other radionuclides, an important milestone on the path towards
accurately characterizing and fully assuring quality of these emerging treatments.
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